Eli Lilly and Co Equity 2025

Eli Lilly and Co Aktienanalyse

What does Eli Lilly and Co do?

Eli Lilly and Co. is a global biopharmaceutical company headquartered in Indianapolis, Indiana, USA. The company was founded in 1876 by Colonel Eli Lilly with the aim of manufacturing pharmaceutical products of the highest quality. Eli Lilly began his career in the pharmacy industry and opened his own pharmacy in Indianapolis in 1876. He quickly developed his own medications and eventually established Eli Lilly and Company in 1901. Over the years, the company has continued to evolve and expand its business into numerous areas. Eli Lilly is focused on biopharmaceutical research and development and operates in areas such as oncology, diabetes, neurology, and others. The company's main goal is to develop drugs that can change and improve lives. Eli Lilly invests a high percentage of its revenue into research and development every year. The company has several strategic business units, including human pharmaceuticals, animal pharmaceuticals, and oncology research. Eli Lilly is divided into five main divisions: diabetes, oncology, immunology, neurology, and animal health. The diabetes division focuses on manufacturing insulin products and glucose sensors for the treatment of type 1 and type 2 diabetes, as well as blood glucose meters and other diabetes products. The oncology division focuses on researching and developing drugs to treat cancer. The company currently has several compounds in clinical trials, including a new preparation for the treatment of breast cancer. The immunology division focuses on products for the treatment of autoimmune and inflammatory diseases, such as psoriasis. The neurology division focuses on researching and developing drugs to treat diseases of the nervous system, such as Alzheimer's. The animal health division focuses on animal health products, such as drugs for the treatment of infections in livestock and pets. Eli Lilly is primarily known for its insulin products and treatments in the field of oncology. Some of the company's most well-known products include Humalog, Forteo, Alimta, and Cymbalta. The effectiveness and compliance of the products are monitored by a quality and safety system to ensure that patients receive the highest quality medications. In conclusion, Eli Lilly and Co. is a company with a long history and a unique business model. The company specializes in developing high-quality pharmaceutical products and has continued to evolve since its founding. Eli Lilly has become a leader in various areas such as diabetes, oncology, immunology, neurology, and animal health. They are known for their insulin products and treatments in the field of oncology. The company remains committed to expanding its reach and presence globally and continues to develop innovative products that can improve and change people's lives. Eli Lilly and Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Eli Lilly and Co's Equity

Eli Lilly and Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Eli Lilly and Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Eli Lilly and Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Eli Lilly and Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Eli Lilly and Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Eli Lilly and Co stock

What is the equity of Eli Lilly and Co this year?

Eli Lilly and Co has equity of 10.77 B USD this year.

What was the equity of Eli Lilly and Co compared to the previous year?

The equity of Eli Lilly and Co has increased/decreased by 1.14% increased compared to the previous year.

What impact does a high equity have on investors of Eli Lilly and Co?

A high equity is advantageous for investors of Eli Lilly and Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Eli Lilly and Co?

A low equity can be a risk for investors of Eli Lilly and Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Eli Lilly and Co affect the company?

An increase in equity of Eli Lilly and Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Eli Lilly and Co affect the company?

A reduction in equity of Eli Lilly and Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Eli Lilly and Co?

Some factors that can affect the equity of Eli Lilly and Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Eli Lilly and Co so important for investors?

The equity of Eli Lilly and Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Eli Lilly and Co take to change the equity?

To change equity, Eli Lilly and Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Eli Lilly and Co pay?

Over the past 12 months, Eli Lilly and Co paid a dividend of 4.52 USD . This corresponds to a dividend yield of about 0.61 %. For the coming 12 months, Eli Lilly and Co is expected to pay a dividend of 5.75 USD.

What is the dividend yield of Eli Lilly and Co?

The current dividend yield of Eli Lilly and Co is 0.61 %.

When does Eli Lilly and Co pay dividends?

Eli Lilly and Co pays a quarterly dividend. This is distributed in the months of June, September, December, March.

How secure is the dividend of Eli Lilly and Co?

Eli Lilly and Co paid dividends every year for the past 26 years.

What is the dividend of Eli Lilly and Co?

For the upcoming 12 months, dividends amounting to 5.75 USD are expected. This corresponds to a dividend yield of 0.77 %.

In which sector is Eli Lilly and Co located?

Eli Lilly and Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eli Lilly and Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eli Lilly and Co from 3/10/2025 amounting to 1.5 USD, you needed to have the stock in your portfolio before the ex-date on 2/14/2025.

When did Eli Lilly and Co pay the last dividend?

The last dividend was paid out on 3/10/2025.

What was the dividend of Eli Lilly and Co in the year 2024?

In the year 2024, Eli Lilly and Co distributed 4.52 USD as dividends.

In which currency does Eli Lilly and Co pay out the dividend?

The dividends of Eli Lilly and Co are distributed in USD.